Sean Brynjelsen compensation by year
Eton Pharmaceuticals Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $172,083 | $332,313 | $409,958 | $475,833 | $542,167 | $569,541 | $591,862 | $615,536 | $712,433 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $210,000 | $0 | $0 | $0 | $0 | $289,300 | $0 | $0 | $936,052 |
| Option awards | $194,600 | $0 | $1,338,750 | $1,305,360 | $1,400,175 | $962,115 | $807,628 | $1,295,283 | $893,712 |
| Non-equity incentive | $77,366 | $150,638 | $186,500 | $218,700 | $138,350 | $286,385 | $334,355 | $487,304 | $354,792 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $10,071 | $11,200 | $11,400 | $11,600 | $12,200 | $13,200 | $13,800 | $17,500 |
| Total | $654,049 | $493,022 | $1,946,408 | $2,011,293 | $2,092,292 | $2,119,541 | $1,747,045 | $2,411,923 | $2,914,489 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Eton Pharmaceuticals, Inc. DEF 14A filed April 24, 2026, accession 0001437749-26-013313, and prior-year filings.
How this page was built: the Eton Pharmaceuticals, Inc. filed document, accession 0001437749-26-013313. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 72,004 | $1,217,588 | — |
| RSU | 27,500 | $465,025 | — |
| Option | 237,593 | — | $4.42 |
| Option | 82,841 | — | $13.00 |
| Option | 102,195 | — | $3.47 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Eton Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Eton Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sean Brynjelsen · this page | President and Chief Executive Officer | $2,914,489 |
| James Gruber | Chief Financial Officer | $1,398,068 |
| David Krempa | Chief Business Officer | $1,394,745 |
| Ipek Erdogan-Trinkaus | Chief Commercial Officer | $575,292 |
The full Eton Pharmaceuticals compensation record
free company briefThis page is one person within Eton Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Eton Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Eton Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.